Psychedelic Research & Clinical Trials
Sunstone is establishing the gold standard for psychedelic clinics to ensure that the delivery of psychedelic-assisted therapy is patient-centric, responsible, safe, and effective.
View All Trials
01
Sunstone designs and delivers innovative clinical trials with leading psychedelic drug developers and medical bodies.
- Beckley Psytech
- COMPASS Pathways
- MindMed
- MAPS (Lykos Therapeutics)
- Reunion Neuroscience
- Usona
02
We work with a broad range of psychedelics.
- MDMA
- Psilocybin
- LSD
- 5-MeO-DMT
03
Across a wide array of clinical indications.
- Adjustment Disorder (AD)
- Demoralization in Patients with Cancer
- End of Life
- Generalized Anxiety Disorder (GAD)
- Major Depressive Disorder (MDD)
- Post-Traumatic Stress Disorder (PTSD)
- Treatment-Resistant Depression (TRD)
04
In partnership with top-tier academic and medical institutions.
- Adventist HealthCare
- Dana-Farber Cancer Institute
- Johns Hopkins Center for Psychedelic & Consciousness Research
- McGill University
- Memorial Sloan Kettering Cancer Center
- The University of Vermont
Sunstone is Developing and Refining the Standards of Patient Care
Discover the Patient ExperienceIndustry Leadership: A Wide Breadth of Clinical Trials
04
Psychedelics
MDMA
Psilocybin
5-MeO-DMT
LSD
07
Treatment Indications
PTSD (Post-Traumatic Stress Disorder)
Demoralization
End of Life
MDD (Major Depressive Disorder)
TRD (Treatment-Resistant Depression)
AD (Adjustment Disorder)
GAD (Generalized Anxiety Disorder)
05
Active Trials in 2024